JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scher, B.
Right arrow Articles by Dresel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scher, B.
Right arrow Articles by Dresel, S.
Journal of Nuclear Medicine Vol. 46 No. 9 1460-1465
© 2005 by Society of Nuclear Medicine


Clinical Investigations

18F-FDG PET/CT for Staging of Penile Cancer

Bernhard Scher, MD1, Michael Seitz, MD2, Martin Reiser, BS1, Edwin Hungerhuber, MD2, Klaus Hahn, MD1, Reinhold Tiling, MD1, Peter Herzog, MD3, Maximilian Reiser, MD3, Peter Schneede, MD2 and Stefan Dresel, MD1

1 Department of Nuclear Medicine, University of Munich, Munich, Germany
2 Department of Urology, University of Munich, Munich, Germany
3 Department of Radiology, University of Munich, Munich, Germany

The value of PET or PET/CT with 18F-FDG for the staging of penile cancer has yet to be determined. The objective of this study was to investigate the pattern of 18F-FDG uptake in the primary malignancy and its metastases and to determine the diagnostic value of 18F-FDG PET/CT in the staging and restaging of penile cancer. Methods: Thirteen patients (mean ± SD age, 64 ± 14.0 y) with suspected penile cancer or suspected recurrent disease were examined with a Gemini PET/CT system (200 MBq of 18F-FDG). The reference standard was based on histopathologic findings obtained at biopsy or during surgery. Results: Both the primary tumor and regional lymph node metastases exhibited a pattern of 18F-FDG uptake typical for malignancy. Sensitivity in the detection of primary lesions was 75% (6/8), and specificity was 75% (3/4). On a per-patient basis, sensitivity in the detection of lymph node metastases was 80% (4/5), and specificity was 100% (8/8). On a nodal-group basis, PET/CT showed a sensitivity of 89% (8/9) in the detection of metastases in the superficial inguinal lymph node basins and a sensitivity of 100% (7/7) in the deep inguinal and obturator lymph node basins. The mean ± SD maximum standardized uptake value for the 8 primary lesions was 5.3 ± 3.7, and that for the 16 lymph node metastases was 4.6 ± 2.0. Conclusion: According to our results, the main indication for 18F-FDG PET in the primary staging or follow-up of penile cancer patients may be the prognostically crucial search for lymph node metastases. With the use of a PET/CT unit, the additional information provided by CT may be especially useful for planning surgery. Implementing 18F-FDG PET and PET/CT in future staging algorithms may lead to a more precise and stage-appropriate therapeutic strategy. Furthermore, invasive procedures with a high morbidity rate, such as general bilateral lymphadenectomy, may be avoided.

Key Words: PET/CT • 18F-FDG • penile cancer


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
J. Czernin, M. Allen-Auerbach, and H. R. Schelbert
Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006
J. Nucl. Med., January 1, 2007; 48(1_suppl): 78S - 88S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.